Pacific Biosciences Of California (PACB) Net Cash Flow (2010 - 2026)

Pacific Biosciences Of California has reported Net Cash Flow for 17 years, with the latest figure at $4.7 million in Q2 2026.

• On a quarterly basis, Net Cash Flow rose 215.85% year-over-year to $4.7 million in Q2 2026; TTM through Jun 2026 was $6.0 million, a 113.23% increase from a year earlier, with the FY2025 full-year figure at $7.7 million, up 106.13% from the prior year.
• Net Cash Flow was $4.7 million for Q2 2026 at Pacific Biosciences Of California, up from -$7.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $176.4 million in Q3 2023, with the low at -$205.7 million in Q4 2023.
• Average Net Cash Flow over 5 years is -$22.4 million, with a median of -$5.1 million recorded in 2022.
• The largest YoY upside for Net Cash Flow was 3033.48% in 2023 against a maximum downside of 1096.02% in 2023.
• Over 5 years, Net Cash Flow stood at $20.7 million in 2022, then tumbled by 1096.02% to -$205.7 million in 2023, then soared by 89.01% to -$22.6 million in 2024, then jumped by 130.78% to $7.0 million in 2025, then sank by 31.85% to $4.7 million in 2026.
• The last three Net Cash Flow figures came in at $4.7 million (Q2 2026), -$7.4 million (Q1 2026), and $7.0 million (Q4 2025), per Business Quant data.